

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set of samples 1**(560) ANA screening (cell nucleus) - prove**

A1	(1) Fluorescent methods		1 Negative	1,3 %
		>>>	69 Positive	90 %
	(2) EIA methods		1 Inconclusive result (borderline)	1,3 %
		>>>	6 Positive	7,8 %
----- Total per sample: n = 77 -----		Success: 97 %		
B1	(1) Fluorescent methods		70 Negative	91 %
	(2) EIA methods		7 Negative	9,1 %
----- Total per sample: n = 77 -----		Success: 100 %		
Total success: 97 %				

(572) ANA screening (cell nucleus) - semi-quantity

A1	(0) Not specified	±	1 titre 80	1,5 %
		±	4 titre 160	6,2 %
		±	12 titre 320	18 %
		±	32 titre 640	49 %
		±	14 titre 1280	22 %
		±	2 titre 2560	3,1 %
----- Total per sample: n = 65 -----		Success (only evaluated results):	evaluation	
B1	(0) Not specified	±	1 Not specified	1,5 %
		±	44 titre 0 (not measurable)	68 %
		±	14 titre 40	22 %
		±	6 titre 80	9,2 %
----- Total per sample: n = 65 -----		Success (only evaluated results):	evaluation	

(561) ANA - type of fluorescence - nucleus

A1	(0) Not specified		6 Homogenous	8,8 %
			1 Homogenous; No fluorescence	1,5 %
			1 Coarse speckled; Fine speckled	1,5 %
			1 Coarse speckled; Midbody pattern (MSA-2)	1,5 %
		>	16 Fine speckled	24 %
			1 Nuclear matrix	1,5 %
		>>>	18 DFS 70	26 %
		>>>	23 DFS 70; Fine speckled	34 %
			1 Unknown type of fluorescence	1,5 %
----- Total per sample: n = 68 -----		Success: 84 %		
B1	(0) Not specified	>>>	68 No fluorescence	100 %
----- Total per sample: n = 68 -----		Success: 100 %		
Total success: 84 %				

(563) ANA screening (cytoplasm) - prove

A1	(1) Fluorescent methods	>>>	57 Negative	86 %
			3 Inconclusive result (borderline)	4,5 %
			6 Positive	9,1 %
----- Total per sample: n = 66 -----		Success: 86 %		
B1	(1) Fluorescent methods	>>>	64 Negative	97 %
			1 Inconclusive result (borderline)	1,5 %
			1 Positive	1,5 %
----- Total per sample: n = 66 -----		Success: 97 %		
Total success: 83 %				

(573) ANA screening (cytoplasm) - semi-quantity

A1	(0) Not specified	±	40 titre 0 (not measurable)	66 %
		±	10 titre 40	16 %
		±	8 titre 80	13 %
		±	2 titre 160	3,3 %
		±	1 titre 320	1,6 %
----- Total per sample: n = 61 -----		Success (only evaluated results):	evaluation	
B1	(0) Not specified	±	41 titre 0 (not measurable)	67 %
		±	14 titre 40	23 %
		±	6 titre 80	9,8 %
----- Total per sample: n = 61 -----		Success (only evaluated results):	evaluation	

(564) ANA - type of fluorescence - cytoplasm

A1	(0) Not specified	>>>	56 No fluorescence	86 %
			2 Granular cytoplasmic pattern (mitochondria)	3,1 %
			6 Fine speckled cytoplasmic pattern	9,2 %
			1 Diffusion cytoplasmic picture	1,5 %
----- Total per sample: n = 65 -----		Success: 86 %		

Test			N	Result	N _{rel}
Sample	Group				
B1	(0) Not specified	>>>	63	No fluorescence	97 %
			1	Diffusion cytoplasmic picture	1,5 %
			1	Cytoskeletal patterns	1,5 %
Total per sample: n = 65		Success: 97 %			
Total success: 83 %					

Set of samples 2**(565) ANCA imunofluorescence - prove**

A2	(1) Fluorescent met. (ethanol)	>>>	45	Positive	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Positive	10 %
	(99) Another measurement principle	>>>	7	Positive	12 %
Total per sample: n = 58		Success: 100 %			
B2	(1) Fluorescent met. (ethanol)	>>>	45	Negative	78 %
	(2) Fluorescent met. (formalin)	>>>	6	Negative	10 %
	(99) Another measurement principle	>>>	7	Negative	12 %
Total per sample: n = 58		Success: 100 %			
Total success: 100 %					

(574) ANCA IF (ethanol) - semi-quantity

A2	(0) Not specified	±	2	titre 20	4,1 %
		±	1	titre 40	2,0 %
		±	7	titre 80	14 %
		±	19	titre 160	39 %
		±	13	titre 320	27 %
		±	6	titre 640	12 %
		±	1	titre 1280	2,0 %
Total per sample: n = 49		Success (only evaluated results): evaluation			
B2	(0) Not specified	±	34	titre 0 (not measurable)	69 %
		±	15	titre 20	31 %
Total per sample: n = 49		Success (only evaluated results): evaluation			

(578) ANCA IF (formalin) - semi-quantity

A2	(0) Not specified	±	2	titre 20	4,7 %
		±	1	titre 40	2,3 %
		±	3	titre 80	7,0 %
		±	10	titre 160	23 %
		±	16	titre 320	37 %
		±	10	titre 640	23 %
		±	1	titre 1280	2,3 %
Total per sample: n = 43		Success (only evaluated results): evaluation			
B2	(0) Not specified	±	28	titre 0 (not measurable)	65 %
		±	15	titre 20	35 %
Total per sample: n = 43		Success (only evaluated results): evaluation			

(566) ANCA - type of fluorescence

A2	(0) Not specified	>>>	56	Cytoplasmic granular fluorescence	100 %
Total per sample: n = 56		Success: 100 %			
B2	(0) Not specified		1	Not specified	1,8 %
		>>>	55	No fluorescence	98 %
Total per sample: n = 56		Success: 98 %			
Total success: 98 %					

(569) anti-myeloperoxidase

A2	(1) Fluorescent methods	>>>	1	Negative	1,5 %
	(2) EIA methods	>>>	51	Negative	77 %
	(5) LIA, ILMA	>>>	3	Negative	4,5 %
	(6) Immunoblotting	>>>	9	Negative	14 %
	(99) Another measurement principle	>>>	2	Negative	3,0 %
Total per sample: n = 66		Success: 100 %			
B2	(1) Fluorescent methods	>>>	1	Negative	1,5 %
	(2) EIA methods	>>>	51	Negative	77 %
	(5) LIA, ILMA	>>>	3	Negative	4,5 %
	(6) Immunoblotting	>>>	9	Negative	14 %
	(99) Another measurement principle	>>>	2	Negative	3,0 %
Total per sample: n = 66		Success: 100 %			
Total success: 100 %					

(570) anti-proteinase III

A2	(2) EIA methods	>>>	51	Positive	77 %
	(5) LIA, ILMA	>>>	3	Positive	4,5 %
	(6) Immunoblotting	>>>	10	Positive	15 %
	(99) Another measurement principle	>>>	2	Positive	3,0 %
Total per sample: n = 66		Success: 100 %			

Test			N	Result	N _{rel}
Sample	Group				
B2	(2) EIA methods	>>>	51	Negative	77 %
	(5) LIA, ILMA	>>>	3	Negative	4,5 %
	(6) Immunoblotting	>>>	10	Negative	15 %
	(99) Another measurement principle	>>>	2	Negative	3,0 %
Total per sample: n = 66		Success: 100 %			
Total success: 100 %					

Set of samples 3**(580) Anti-ENA/SS-A/Ro-60**

A3	(2) EIA methods	>>>	35	Negative	49 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	34	Negative	48 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
B3	(2) EIA methods	>>>	35	Positive	49 %
	(5) LIA, ILMA	>>>	1	Positive	1,4 %
	(6) Immunoblotting	>>>	34	Positive	48 %
	(99) Another measurement principle	>>>	1	Positive	1,4 %
Total per sample: n = 71		Success: 100 %			
Total success: 100 %					

(581) Anti-ENA/SS-B/La

A3	(2) EIA methods	>>>	34	Negative	48 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
B3	(2) EIA methods	>>>	34	Positive	48 %
	(5) LIA, ILMA	>>>	1	Positive	1,4 %
	(6) Immunoblotting	>>>	35	Positive	49 %
	(99) Another measurement principle	>>>	1	Positive	1,4 %
Total per sample: n = 71		Success: 100 %			
Total success: 100 %					

(582) Anti-ENA/Sci-70

A3	(2) EIA methods	>>>	34	Negative	48 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
B3	(2) EIA methods	>>>	34	Negative	48 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
Total success: 100 %					

(583) Anti-ENA/RNP

A3	(1) Fluorescent methods	>>>	1	Negative	1,4 %
	(2) EIA methods	>>>	33	Negative	46 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
B3	(1) Fluorescent methods	>>>	1	Negative	1,4 %
	(2) EIA methods	>>>	33	Negative	46 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
Total success: 100 %					

(584) Anti-ENA/Jo-1

A3	(2) EIA methods	>>>	33	Negative	46 %
			1	Inconclusive result (borderline)	1,4 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %
	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 99 %			
B3	(2) EIA methods	>>>	34	Negative	48 %
	(5) LIA, ILMA	>>>	1	Negative	1,4 %

Test					
Sample	Group		N	Result	N _{rel}
B3	(6) Immunoblotting	>>>	35	Negative	49 %
	(99) Another measurement principle	>>>	1	Negative	1,4 %
Total per sample: n = 71		Success: 100 %			
Total success: 99 %					

(585) Anti-centromere antibodies

A3	(0) Not specified	>>>	3	Negative	4,9 %
	(1) Fluorescent methods	>>>	5	Negative	8,2 %
	(2) EIA methods	>>>	16	Negative	26 %
	(5) LIA, ILMA	>>>	1	Negative	1,6 %
	(6) Immunoblotting	>>>	35	Negative	57 %
	(99) Another measurement principle	>>>	1	Negative	1,6 %
Total per sample: n = 61		Success: 100 %			
B3	(0) Not specified	>>>	3	Negative	4,9 %
	(1) Fluorescent methods	>>>	5	Negative	8,2 %
	(2) EIA methods	>>>	16	Negative	26 %
	(5) LIA, ILMA	>>>	1	Negative	1,6 %
	(6) Immunoblotting	>>>	35	Negative	57 %
	(99) Another measurement principle	>>>	1	Negative	1,6 %
Total per sample: n = 61		Success: 100 %			
Total success: 100 %					

Set of samples 4**(588) Anti-ds-DNA immunofluores.**

A4	(0) Not specified	>>>	51	Negative	100 %
Total per sample: n = 51		Success: 100 %			
B4	(0) Not specified	>>>	51	Positive	100 %
Total per sample: n = 51		Success: 100 %			
Total success: 100 %					

(577) Anti-ds-DNA immunofluor. - semi-quantity

A4	(0) Not specified	±	34	titre 0 (not measurable)	69 %
		±	15	titre 10	31 %
Total per sample: n = 49		Success (only evaluated results): evaluation			
B4	(0) Not specified	±	1	titre 10	2,0 %
		±	1	titre 40	2,0 %
		±	5	titre 80	10 %
		±	18	titre 160	37 %
		±	12	titre 320	24 %
		±	10	titre 640	20 %
		±	2	titre 1280	4,1 %
Total per sample: n = 49		Success (only evaluated results): evaluation			

(589) Anti-ds-DNA other methods

A4	(2) EIA methods	>>>	36	Negative	73 %
	(5) LIA, ILMA	>>>	3	Negative	6,1 %
	(6) Immunoblotting	>>>	8	Negative	16 %
	(99) Another measurement principle	>>>	2	Negative	4,1 %
Total per sample: n = 49		Success: 100 %			
B4	(2) EIA methods	>>>	36	Positive	73 %
	(5) LIA, ILMA	>>>	3	Positive	6,1 %
	(6) Immunoblotting	>>>	8	Positive	16 %
	(99) Another measurement principle	>>>	2	Positive	4,1 %
Total per sample: n = 49		Success: 100 %			
Total success: 100 %					

Set of samples 5**(591) Anti-nucleosomes IgG**

A5	(2) EIA methods	>>>	34	Negative	71 %
	(6) Immunoblotting	>>>	14	Negative	29 %
Total per sample: n = 48		Success: 100 %			
B5	(2) EIA methods	>>>	34	Positive	71 %
	(6) Immunoblotting	>>>	14	Positive	29 %
Total per sample: n = 48		Success: 100 %			
Total success: 100 %					